International GLP-1 Access: Pricing Abroad, Personal Import, and Counterfeit Risks

The 10x price differences between U.S. and other countries are real. What personal importation rules actually allow, the counterfeit landscape, and why domestic options usually make more sense.

Wegovy in the United States costs approximately $1,349 per month at list price. Wegovy in the United Kingdom costs roughly £175 per month through the NHS when covered. In India, semaglutide is approved under different branding and costs a fraction of U.S. prices. In Mexico, semaglutide is available at substantially lower costs than in the U.S. In Canada, semaglutide is covered by many provincial health systems at minimal patient cost but not covered for weight loss through government programs.

These pricing differences raise a natural question for patients facing high U.S. costs: can you legitimately access GLP-1 medications from other countries, and what does that actually look like?

Here's the honest landscape in 2026.

Why Prices Differ So Much

The main drivers of international GLP-1 price variation:

Government Price Negotiation

Most developed countries have government health systems or insurance systems that negotiate drug prices directly with manufacturers. The UK NHS, German statutory insurance, Canadian provincial systems, and Australian PBS all negotiate substantial discounts on pharmaceutical pricing. The U.S. system historically has not done this for most medications, producing much higher list prices.

Different Manufacturing and Distribution

In some countries, generic or biosimilar versions of medications may be available years before U.S. patents expire. In others, local manufacturing produces the same molecule at lower cost.

Parallel Trade

Some countries participate in pharmaceutical parallel trade — importing medications from lower-priced markets within regional trade agreements (e.g., within the EU).

Income-Based Access Programs

Developing countries often have specific pricing arrangements with manufacturers to allow broader access. India, Brazil, and others benefit from these programs.

The Legal Framework for U.S. Patients

U.S. law around importing prescription medications is complex and includes several relevant principles:

Formal Legal Position: Generally Not Allowed

Under federal law, importing prescription medications from other countries is generally prohibited. Only medications approved by the FDA and manufactured in facilities inspected by the FDA are technically legal in the U.S.

Personal Importation Exception

FDA has a long-standing policy of "enforcement discretion" for personal importation when several conditions are met:

• The medication is for personal use, not commercial
• No more than a 90-day supply at a time
• The medication is for a serious condition not adequately treated by available U.S. options
• The product is verifiable as identical to an FDA-approved product
• The patient provides relevant information about the medication to their U.S. healthcare provider

In practice, FDA rarely takes action against individuals importing small quantities of medications for personal use. But the legal basis for such importation is limited, and FDA has discretion to seize shipments.

State-Level Variation

Some states have passed laws attempting to create importation programs from Canada or other countries. The federal legal status remains complex.

Common International Sourcing Scenarios

1. Traveling Abroad

Patients traveling internationally sometimes fill prescriptions abroad for use during or after the trip. Legal considerations:

• Carrying prescription medications for personal use during travel is generally legal, both in the departure country and in the U.S. upon return
• Amounts should match expected duration of use — 90-day supplies or less
• Original packaging with pharmacy labels should be maintained
• Documentation from prescribers is helpful if questioned at customs

Some patients intentionally travel to lower-cost countries to fill prescriptions. This is technically allowed for personal use, though FDA discretion applies.

2. International Pharmacies Shipping to U.S.

Websites claiming to be Canadian, European, or other international pharmacies have been shipping medications to U.S. customers for years. Legal and safety considerations:

• Many of these operations are not located where they claim to be. A site advertising itself as a "Canadian pharmacy" may actually be operating from India, Mexico, or other jurisdictions
• Counterfeit medications are a significant risk. FDA has documented cases of counterfeit semaglutide and tirzepatide in international supply chains
• Legitimate international pharmacies exist but can be difficult to distinguish from illegitimate ones
• Customs can seize shipments even when the medications are legitimate

3. Medical Tourism

Some patients travel specifically to obtain medications at lower prices — Mexico for prescription drugs, India for specialty medications. Considerations:

• Ensuring the product obtained is actually the medication you believe it to be
• Cold chain maintenance during return travel with refrigerated medications
• Ongoing supply logistics (you still need to access medication after the initial trip)
• Follow-up care continuity with your primary prescriber

4. Expatriates and International Patients

U.S. patients living temporarily or permanently abroad face different calculations. Local healthcare systems often offer much lower GLP-1 prices with different insurance dynamics. Returning expats sometimes continue using prescriptions from their time abroad, which requires careful coordination with U.S. providers.

Where Prices Are Much Lower

Approximate GLP-1 pricing landscape in 2026 (subject to change):

These prices are approximate and change with currency fluctuations, regulatory changes, and local market conditions.

The Counterfeit Risk

International sourcing brings real counterfeit risk. FDA and INTERPOL have documented numerous cases of fake semaglutide and tirzepatide in international supply chains:

• Products labeled as brand-name GLP-1s but containing nothing or different chemicals
• Products with correct-looking labels but manufactured in unregulated facilities
• Reused or refilled pens sold as new
• Products contaminated with bacteria, other medications, or toxic substances

Indicators of possible counterfeits:

• Price far below even normal international prices (genuine products have baseline manufacturing costs)
• Shipping from unexpected countries or via routes that don't match the claimed origin
• Packaging with minor differences from official products (spelling, colors, fonts)
• No prescription required
• Unusually aggressive marketing or pressure tactics
• Claims of being "the same product for less" without a plausible explanation

Better Alternatives for Most U.S. Patients

For U.S. patients seeking lower GLP-1 costs, better options than international sourcing typically include:

1. Manufacturer Direct-to-Consumer

LillyDirect vial Zepbound: $349–700/month depending on dose. NovoCare Wegovy: similar pricing. These are legitimate, FDA-approved, and have stable supply.

2. Oral Options at $149/month

Foundayo (orforglipron) and Wegovy pill both launched with $149/month starting-dose pricing. Legitimate, straightforward, no international sourcing concerns.

3. Patient Assistance Programs

Both Lilly and Novo have income-based patient assistance programs that can provide medication at no cost for qualifying patients. Income limits vary but typically allow access for those below 400–500% of federal poverty level.

4. Manufacturer Savings Cards

For commercially-insured patients, savings cards can bring copays to as low as $25/month.

5. HSA/FSA

22–37% effective savings depending on tax bracket, as covered elsewhere.

These domestic alternatives generally produce better outcomes (legal certainty, supply reliability, product quality) than international sourcing for most U.S. patients.

For Non-U.S. Readers

This guide focuses on U.S. patients, but some points for patients in other countries:

• Local GLP-1 pricing and access varies dramatically by country and health system
• Many countries have stricter obesity indication criteria than the U.S. for insurance coverage
• Self-pay pricing is typically well below U.S. levels even without insurance
• Local patient assistance programs may exist through manufacturers
• Medical tourism from high-priced to lower-priced countries is sometimes done, though logistics vary

Country-specific advice from local obesity medicine providers is the appropriate source for detailed access information.

If You're Considering International Sourcing Anyway

Some patients, for various reasons, will pursue international sourcing despite the cautions. Practical advice if you do:

• Work through pharmacies recommended by trusted consumer-protection organizations (e.g., specific Canadian pharmacies verified by third parties)
• Maintain a U.S. prescribing relationship for medical management regardless of where you get the medication
• Inspect products carefully for authenticity markers
• Consider cost vs risk — if savings are modest compared to legitimate alternatives, the risk isn't worth it
• Keep your U.S. prescriber informed about what you're actually taking
• Report any suspicious products to FDA's MedWatch program

Questions Worth Asking Before International Sourcing

• Have I explored all the domestic options — manufacturer direct-to-consumer, oral alternatives, patient assistance programs, HSA/FSA?
• Is the cost savings substantial enough to justify the risks (counterfeit exposure, customs seizure, legal complications)?
• How will I verify the medication's authenticity?
• How will I handle ongoing prescription management from a U.S. provider?
• What's my backup plan if international shipments stop being available?